Arcellx Announces Participation at the Morgan Stanley 20th Annual Global Healthcare ConferencePRNewsWire • 09/07/22
Arcellx Provides Business Highlights and Reports Second Quarter 2022 Financial ResultsPRNewsWire • 08/15/22
Arcellx Announces Closing of Upsized Public Offering of Common Stock and Underwriters' Full Exercise of Option to Purchase Additional SharesPRNewsWire • 06/21/22
Arcellx Presents Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 2022 ASCO Annual MeetingPRNewsWire • 06/03/22
Biotech stocks get a boost, or plunge, as new clinical data is shared before major cancer meetingMarket Watch • 05/27/22
Arcellx Provides Business Updates and Reports First Quarter 2022 Financial ResultsPRNewsWire • 05/12/22
Arcellx Announces Dosing of First Patient in its Phase 1 Clinical Trial Evaluating ACLX-001, the First Therapeutic in the Dosable and Controllable ARC-SparX Platform, for the treatment of Patients with Relapsed or Refractory Multiple MyelomaPRNewsWire • 05/10/22
Arcellx Announces Publication in Blood Advances of Clinical Results from the Dose Escalation Cohorts of its CART-ddBCMA Phase 1 Study in Patients with Relapsed or Refractory Multiple MyelomaPRNewsWire • 05/09/22
Arcellx Announces Participation at the BofA Securities 2022 Healthcare ConferencePRNewsWire • 05/05/22
Arcellx to Present New Clinical Data from its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma in an Oral Abstract Session at the 2022 American Society of Clinical Oncology (ASCO) Annual MeetingPRNewsWire • 04/27/22
Arcellx Presents Pre-Clinical Data for ACLX-002, a Novel CD123-targeted Universal CAR-T Cell Therapy for Relapsed or Refractory Acute Myeloid Leukemia at the American Association for Cancer Research Annual MeetingPRNewsWire • 04/08/22
Arcellx Provides Business Update and Reports Fourth Quarter and Year-End 2021 Financial ResultsPRNewsWire • 03/24/22
Arcellx Announces Pre-Clinical Data Presentation for ACLX-002, a Novel CD123-targeted Universal CAR-T Cell Therapy for Relapsed or Refractory Acute Myeloid Leukemia at the American Association for Cancer Research Annual Meeting 2022PRNewsWire • 03/08/22
Arcellx Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 02/08/22
CAR-T Player Arcellx Raises $123M Via Initial Public Offering, Opens Trading At $19Benzinga • 02/04/22